Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Chintox in primary blepharospasm
CTR20244904Phase 2Active
- Sponsor
- Lanzhou Biotechnology Development
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of lanbotulinumtoxin-A in idiopathic blepharospasm (BEB), sponsored by Lanzhou Biotechnology Development. Started Jan 2026; status: active.
02
Drugs
lanbotulinumtoxin-A
03
Conditions
idiopathic blepharospasm (BEB)
Beyond the preview
Go deeper on CTR20244904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244904.